Table 2.
Univariate analysis of the training cohort.
| Variables | Survivor (n = 58) | Nonsurvivor (n = 39) | P value |
| Sex (male, n%) | 27 (46.55%) | 22 (56.41%) | .34∗ |
| Age (y) | 68.00 (61.00, 73.25) | 71.00 (67.00, 84.00) | .01‡ |
| Comorbidities | 40 (68.97%) | 32 (82.05%) | .15∗ |
| Hypertension | 23 (39.66%) | 20 (51.28%) | .26∗ |
| Diabetes | 13 (22.41%) | 9 (23.08%) | .94∗ |
| Coronary heart disease | 6 (10.34%) | 8 (20.51%) | .16∗ |
| Chronic obstructive pulmonary disease | 4 (6.90%) | 6 (15.38%) | .18∗ |
| Cerebrovascular disease | 3 (5.17%) | 4 (10.26%) | .34∗ |
| White blood cell count (×109/L) | 6.40 (5.30, 9.18) | 8.20 (6.00, 12.00) | .08‡ |
| Neutrophil count (×109/L) | 4.43 (3.20, 7.05) | 6.75 (4.89, 10.54) | .01‡ |
| Lymphocyte count (×109/L) | 1.10 (0.71, 1.58) | 0.56 (0.35, 0.81) | <.001‡ |
| Haemoglobin (g/L) | 117.97 ± 18.29 | 110.69 ± 24.12 | .09† |
| Platelet count (×109/L) | 223.83 ± 80.81 | 163.15 ± 101.20 | <.01† |
| Albumin (g/L) | 33.42 ± 3.77 | 31.01 ± 4.53 | .01† |
| Lactate dehydrogenase (U/L) | 242.63 (180.30, 329.13) | 410.40 (294.96, 616.00) | <.001‡ |
| Creatine kinase (U/L) | 43.15 (27.38, 69.19) | 76.40 (44.50, 157.00) | <.001‡ |
| C-reactive protein (mg/L) | 11.55 (2.34, 62.15) | 66.85 (11.81, 134.76) | <.01‡ |
| Prothrombin time (s) | 13.27 (12.38, 14.35) | 15.40 (13.26, 16.46) | <.001‡ |
| Activated partial thromboplastin time (s) | 27.31 (25.49, 29.33) | 30.41 (26.61, 33.70) | <.01‡ |
| D-dimer (mg/L) | 1.04 (0.51, 1.96) | 2.98 (1.37, 6.57) | <.001‡ |
| Liver injury | 12 (20.69%) | 10 (25.64%) | .57∗ |
| Renal injury | 3 (5.17%) | 7 (17.95%) | .04∗ |
| DIC score | 0 (0, 0) | 1 (0, 3) | <.001‡ |
DIC, disseminated intravascular coagulation.
∗
Pearson Chi-Squared test.
†
t test.
‡
Mann–Whitney test.